Literature DB >> 16614725

The A148T variant of the CDKN2A gene is not associated with melanoma risk in the French and Italian populations.

Tania Spica, Marc Portela, Bénédicte Gérard, Federica Formicone, Vincent Descamps, Béatrice Crickx, Laurence Ollivaud, Alain Archimbaud, Nicolas Dupin, Pierre Wolkenstein, Dominique Vitoux, Céleste Lebbe, Philippe Saiag, Nicole Basset-Seguin, Maria Concetta Fargnoli, Bernard Grandchamp, Ketty Peris, Nadem Soufir.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16614725     DOI： 10.1038/sj.jid.5700293

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  9 in total

1.  CDKN2A and MC1R variants found in Cypriot patients diagnosed with cutaneous melanoma.

Authors:  Georgia Koulermou; Christos Shammas; Andreas Vassiliou; Tassos C Kyriakides; Constantina Costi; Vassos Neocleous; Leonidas A Phylactou; Maria Pantelidou
Journal:  J Genet       Date:  2017-03       Impact factor: 1.166

2.  Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma.

Authors:  Anne Guyot; Mathilde Duchesne; Sandrine Robert; Anne-Sophie Lia; Paco Derouault; Erwan Scaon; Leslie Lemnos; Henri Salle; Karine Durand; François Labrousse
Journal:  J Neurooncol       Date:  2019-11-15       Impact factor: 4.130

3.  Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling.

Authors:  Robert R McWilliams; Eric D Wieben; Kari G Rabe; Katrina S Pedersen; Yanhong Wu; Hugues Sicotte; Gloria M Petersen
Journal:  Eur J Hum Genet       Date:  2010-12-08       Impact factor: 4.246

4.  Genetic counseling in melanoma.

Authors:  Celia Badenas; Paula Aguilera; Joan A Puig-Butillé; Cristina Carrera; Josep Malvehy; Susana Puig
Journal:  Dermatol Ther       Date:  2012 Sep-Oct       Impact factor: 2.851

5.  Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom.

Authors:  Mark Harland; Anne E Cust; Celia Badenas; Yu-Mei Chang; Elizabeth A Holland; Paula Aguilera; Joanne F Aitken; Bruce K Armstrong; Jennifer H Barrett; Cristina Carrera; May Chan; Joanne Gascoyne; Graham G Giles; Chantelle Agha-Hamilton; John L Hopper; Mark A Jenkins; Peter A Kanetsky; Richard F Kefford; Isabel Kolm; Johanna Lowery; Josep Malvehy; Zighereda Ogbah; Joan-Anton Puig-Butille; Jordi Orihuela-Segalés; Juliette A Randerson-Moor; Helen Schmid; Claire F Taylor; Linda Whitaker; D Timothy Bishop; Graham J Mann; Julia A Newton-Bishop; Susana Puig
Journal:  Hered Cancer Clin Pract       Date:  2014-11-20       Impact factor: 2.857

6.  Variants at the 9p21 locus and melanoma risk.

Authors:  Livia Maccioni; Panduranga Sivaramakrishna Rachakonda; Justo Lorenzo Bermejo; Dolores Planelles; Celia Requena; Kari Hemminki; Eduardo Nagore; Rajiv Kumar
Journal:  BMC Cancer       Date:  2013-07-02       Impact factor: 4.430

7.  Significance of CDKN2A gene A148T variant in patients with bladder cancer.

Authors:  Edyta Borkowska; Adam Jędrzejczyk; Andrzej Kruk; Michał Pietrusiński; Magdalena Traczyk; Marek Rożniecki; Bogdan Kałużewski
Journal:  Cent European J Urol       Date:  2011-09-06

8.  Effect of tumor suppressor gene cyclin-dependent kinase inhibitor 2A wild-type and A148T mutant on the cell cycle of human ovarian cancer cells.

Authors:  Zehua Bian; Yang Yu; Terigele Yang; Chao Quan; Wenjing Sun; Songbin Fu
Journal:  Oncol Lett       Date:  2014-02-11       Impact factor: 2.967

9.  CDKN2A Polymorphism in Melanoma Patients in Colombian Population: A Case-Control Study.

Authors:  Jose D Tovar-Parra; Luz D Gutiérrez-Castañeda; Sebastián R Gil-Quiñones; Jhon A Nova; Leonardo Pulido
Journal:  Biomed Res Int       Date:  2020-10-10       Impact factor: 3.411
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.